Stem Cell IV in Korea Sorting Research From Sales Talk

Sellers rarely separate strong research from weak, so sort what they show you first. Only the top grade says much about people receiving a named product.

Note which grade a brochure actually reaches. A pile of lower-grade items does not add up to a higher grade.

Yim and colleagues presented a systematic review and meta-analysis in Cytotherapy in 2016 on the safety of mesenchymal stem cell therapy, a cell type often named when cell products are discussed. A review of this design pools published studies, which places it at the top of the ladder above.

Its limits matter just as much. Clinical studies generally run on characterized products, screened volunteers and planned follow-up under a protocol. A wellness drip with an unnamed product, no screening and no follow-up shares none of those conditions, so a reassuring pooled safety record cannot simply be borrowed by it. Ask whether the product in front of you was ever part of such a trial.

Master, Matthews and Abou-el-Enein, writing in Stem Cell Reports in 2021, set out how regulators in the United States and the European Union sort cell products. The terms are worth learning because a product sheet that avoids them is hiding its category.

Spinning blood in a centrifuge, filtering or freezing counts as light handling. Growing cells in culture or digesting tissue with enzymes counts as substantial handling, and that pushes a product into the medicine category with much stricter oversight. A second test asks whether the cells do the same job in the new site as in the original tissue.

• Same person or donor: are the cells yours or someone else's?
• Light or substantial handling: centrifuged only, or grown in culture?
• Same job or new job: is the tissue used for its original function?

The same paper lists how providers of unproven cell interventions present their products as scientific. They overstate benefits, play down risks and leave out details that could lose a sale. Some point to animal studies or articles that only look scientific, obtain approval from paid ethics boards of doubtful standing, or list a pay-to-take-part study on a public registry, which nobody checks for quality.

The authors also listed Korea among 26 countries with documented clinics marketing such interventions, and they describe injuries and deaths after unproven products.

Turn any study or approval claim into checkable facts. A real study can be named, and a real approval names an authority and a use.

• The registry number of the study, plus its phase and sponsor
• Whether participants pay to join, which proper trials normally avoid
• The name of the ethics committee and the institution behind it
• The authority that granted any approval, and for which exact use
• Whether the cited paper tested this product, by this vein route